Reminder: Invitation to the Roche Diagnostics Investor Day 2021: Innovating diagnostics, shaping healthcare, changing lives
March 15, 2021 at 02:35 pm IST
Share
Investor Update
Reminder: Invitation to the Roche Diagnostics Investor Day 2021: Innovating diagnostics, shaping healthcare, changing lives
We are pleased to invite investors and analysts to participate in our virtual event on Tuesday, 23 March 2021 highlighting future growth drivers of the Division.
We will welcome you to the event in our new virtual 360° platform which will be accessible one day prior to the event (as of 15:00 CET). We would like to invite you to visit our virtual marketplace and participate in a self-guided virtual showroom tour. Stay tuned!
14:00-16:00 CET / 13:00-15:00 GMT
9:00-11:00am EDT / 6:00-8:00am PDT
The event will address the following topics:
Diagnostics market opportunities, strategy and organisation
Overview on R&D and new technologies
Late stage pipeline: Systems and diagnostics solutions for selected disease areas such as infectious diseases, cardiology and oncology
Speakers will include:
Thomas Schinecker, CEO Roche Diagnostics
Ann Costello, Global Head Roche Diagnostics Solutions
Palani Kumaresan, Global Head of Research & Development
Benjamin Lilienfeld, Life Cycle Leader Serum Work Area Systems
Michael Hombach, Global Clinical Leader Infectious Diseases
Andre Ziegler, Global Clinical Leader Cardiology
Jill German, Global Head of Pathology Lab
The webinar will start with presentations, followed by a Q&A session (live access to the speakers).
If you want to benefit from the entire platform (e.g. visit of virtual showroom) please register here by today, 15 March 2021.
A replay of the event will be available via >ir.roche.com
*privacy notice
Best regards,
Karl Mahler Birgit Masjost
Head of Investor Relations and Investor Relations Officer
Roche Group Planning
Roche Investor Relations
Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com
Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com
Jon Kaspar Bayard
Phone: +41 61 68-83894
e-mail: jon_kaspar.bayard@roche.com
Lisa Tuomi
Phone: +1 650 467 8737
e-mail: tuomi.lisa@gene.com
Attachments
Original document
Permalink
Disclaimer
Roche Holding AG published this content on 15 March 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 March 2021 09:04:04 UTC.
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.